The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study.
Arterial thrombosis
Cardiovascular disease
Deficiency of natural coagulation inhibitors
Inherited thrombophilia
Ischemic stroke
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
09
09
2020
accepted:
23
01
2021
pubmed:
24
2
2021
medline:
22
9
2021
entrez:
23
2
2021
Statut:
ppublish
Résumé
Whether the carriership of inherited antithrombin (AT), protein C (PC), and protein S (PS) deficiency increases the risk of arterial thromboembolic events (ATE) is controversial. This information has the potential to inform the management of family members of probands with inherited deficiency of natural anticoagulants. We conducted a large prospective family cohort study in 640 subjects (of whom 341 carriers and 299 non-carriers) belonging to 86 families with inherited deficiency of AT, PC, or PS. A total of 4240 and 3810 patient-years were available for carriers and non-carriers, respectively. Risk factors for atherosclerosis were similarly distributed in the two groups. Of the 26 ATE that were recorded, 19 occurred in carriers (5.6%), as compared to 7 in non-carriers (2.3%) [p = 0.07]. After adjusting for confounders, the hazard ratio (HR) for ATE was 4.9 (95% CI 1.5-16.3) in carriers as compared to non-carriers. Among family members of probands with an inherited deficiency of natural anticoagulants, carriers exhibit a risk of ATE that is almost five times higher than in non-carriers.
Sections du résumé
BACKGROUND
BACKGROUND
Whether the carriership of inherited antithrombin (AT), protein C (PC), and protein S (PS) deficiency increases the risk of arterial thromboembolic events (ATE) is controversial. This information has the potential to inform the management of family members of probands with inherited deficiency of natural anticoagulants.
PATIENTS/METHODS
METHODS
We conducted a large prospective family cohort study in 640 subjects (of whom 341 carriers and 299 non-carriers) belonging to 86 families with inherited deficiency of AT, PC, or PS.
RESULTS
RESULTS
A total of 4240 and 3810 patient-years were available for carriers and non-carriers, respectively. Risk factors for atherosclerosis were similarly distributed in the two groups. Of the 26 ATE that were recorded, 19 occurred in carriers (5.6%), as compared to 7 in non-carriers (2.3%) [p = 0.07]. After adjusting for confounders, the hazard ratio (HR) for ATE was 4.9 (95% CI 1.5-16.3) in carriers as compared to non-carriers.
CONCLUSIONS
CONCLUSIONS
Among family members of probands with an inherited deficiency of natural anticoagulants, carriers exhibit a risk of ATE that is almost five times higher than in non-carriers.
Identifiants
pubmed: 33619677
doi: 10.1007/s11739-021-02656-5
pii: 10.1007/s11739-021-02656-5
pmc: PMC8195788
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
997-1003Commentaires et corrections
Type : CommentIn
Références
De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzi B, Mannucci PM (1994) Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 72(3):352–358
doi: 10.1055/s-0038-1648870
Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, Gavasso S, Huisman MV, Buller HR, Wouter ten Cate J, Girolami A, Prins MH (1999) Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 81(2):198–202
doi: 10.1055/s-0037-1614442
Sanson BJ, Simioni P, Tormene D, Moia M, Friederich PW, Huisman MV, Prandoni P, Bura A, Rejto L, Wells P, Mannucci PM, Girolami A, Buller HR, Prins MH (1999) The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood 94(11):3702–3706
pubmed: 10572082
Girolami A, Simioni P, Scarano L, Girolami B (1997) Venous and arterial thrombophilia. Haematologica 82(1):96–100
pubmed: 9107094
Boekholdt SM, Kramer MH (2007) Arterial thrombosis and the role of thrombophilia. Semin Thromb Hemost 33(6):588–596
doi: 10.1055/s-2007-985755
Prandoni P (2020) Is there a link between venous and arterial thrombosis? A reappraisal. Internal Emerg Med 15(1):33–36
doi: 10.1007/s11739-019-02238-6
Simioni P, Zanardi S, Saracino A, Girolami A (1992) Occurrence of arterial thrombosis in a cohort of patients with hereditary deficiency of clotting inhibitors. J Med 23(1):61–74
pubmed: 1533414
Rallidis LS, Belesi CI, Manioudaki HS, Chatziioakimidis VK, Fakitsa VC, Sinos LE, Laoutaris NP, Apostolou TS (2003) Myocardial infarction under the age of 36: prevalence of thrombophilic disorders. Thromb Haemost 90(2):272–278
pubmed: 12888875
Segev A, Ellis MH, Segev F, Friedman Z, Reshef T, Sparkes JD, Tetro J, Pauzner H, David D (2005) High prevalence of thrombophilia among young patients with myocardial infarction and few conventional risk factors. Int J Cardiol 98(3):421–424
doi: 10.1016/j.ijcard.2003.10.057
Vossen CY, Rosendaal FR, E.S. Group (2006) Risk of arterial thrombosis in carriers of familial thrombophilia. J Thromb Haemost JTH 4(4):916–918
doi: 10.1111/j.1538-7836.2006.01838.x
Mahmoodi BK, Brouwer JL, Veeger NJ, van der Meer J (2008) Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 118(16):1659–1667
doi: 10.1161/CIRCULATIONAHA.108.780759
Mahmoodi BK, Veeger NJ, Middeldorp S, Lijfering WM, Brouwer JL, Ten Berg J, Hamulyak K, Meijer K (2016) Interaction of hereditary thrombophilia and traditional cardiovascular risk factors on the risk of arterial thromboembolism: pooled analysis of four family cohort studies. Circ Cardiovasc Genet 9(1):79–85
doi: 10.1161/CIRCGENETICS.115.001211
Tormene D (2015) The incidence of VTE in asymptomatic carriers of a deficiency of at, PC OR PS: a prospective cohort study. , OR078 Abstracts of the XXV congress of the international society on thrombosis and haemostasis
Nelson RH (2013) Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care 40(1):195–211
doi: 10.1016/j.pop.2012.11.003
Book (2003) Report of the expert committee on the diagnosis and classification of diabete mellitus
Bulato C, Tognin G, Spiezia L, Fadin M, Gavasso S, Simioni P (2013) Identification of a novel frameshift mutation causing a premature stop codon in a young Nigerian man with type I antithrombin deficiency. Thromb Res 131(5):463–465
doi: 10.1016/j.thromres.2013.01.032
Castoldi E, Maurissen LF, Tormene D, Spiezia L, Gavasso S, Radu C, Hackeng TM, Rosing J, Simioni P (2010) Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency. Haematologica 95(9):1563–1571
doi: 10.3324/haematol.2010.021923
Michiels JJ, Hamulyak K (1998) Laboratory diagnosis of hereditary thrombophilia. Semin Thromb Hemost 24(4):309–320
doi: 10.1055/s-2007-996019
Liu D, Guo H, Griffin JH, Fernandez JA, Zlokovic BV (2003) Protein S confers neuronal protection during ischemic/hypoxic injury in mice. Circulation 107(13):1791–1796
doi: 10.1161/01.CIR.0000058460.34453.5A
Rezende SM, Simmonds RE, Lane DA (2004) Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex. Blood 103(4):1192–1201
doi: 10.1182/blood-2003-05-1551
Mosnier LO, Griffin JH (2006) Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Front Biosci J Virtual Libr 11:2381–2399
doi: 10.2741/1977
Mosnier LO, Zlokovic BV, Griffin JH (2007) The cytoprotective protein C pathway. Blood 109(8):3161–3172
doi: 10.1182/blood-2006-09-003004